{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:40:34Z","timestamp":1791999634626,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jaad.2024.11.064","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T07:59:44Z","timestamp":1734595184000},"page":"781-789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study"],"prefix":"10.1016","volume":"92","author":[{"given":"Yuji","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Adiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranab","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Napatalung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2024.11.064_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s13671-014-0098-6","article-title":"The epidemiology of vitiligo","volume":"4","author":"Silverberg","year":"2015","journal-title":"Curr Dermatol Rep"},{"key":"10.1016\/j.jaad.2024.11.064_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial effects of vitiligo: a systematic literature review","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib3","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/bjd.15933","article-title":"Quality of life in people with vitiligo: a systematic review and meta-analysis","volume":"177","author":"Morrison","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/ipj.ipj_16_20","article-title":"Assessment of quality of life in vitiligo patients attending a tertiary care hospital - a cross sectional study","volume":"30","author":"Baidya","year":"2021","journal-title":"Ind Psychiatry J"},{"key":"10.1016\/j.jaad.2024.11.064_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"New discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib6","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jid.2021.09.015","article-title":"Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through Jak signaling","volume":"142","author":"Martins","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: a review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2024.11.064_bib8","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.3390\/ijms25084409","article-title":"Pathogenesis of alopecia areata and vitiligo: commonalities and differences","volume":"25","author":"Yamaguchi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2024.11.064_bib9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2017.0002","article-title":"Phototherapy for vitiligo: a systematic review and meta-analysis","volume":"153","author":"Bae","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib10","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2024.11.064_bib11","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/jdv.19450","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international Vitiligo Task Force-Part 2: specific treatment recommendations","volume":"37","author":"Seneschal","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2024.11.064_bib12","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/jid.2015.126","article-title":"Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors","volume":"135","author":"Goldstein","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/phpp.12275","article-title":"Repigmentation patterns induced by NB-UVB and their relationship with melanocytic migration and proliferation in vitiligo","volume":"32","author":"Castanedo-C\u00e1zares","year":"2016","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2024.11.064_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2024.11.064_bib15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","article-title":"Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy","volume":"154","author":"Kim","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","article-title":"Repigmentation in vitiligo using Janus kinase (JAK) inhibitors with phototherapy: systematic review and meta-analysis","volume":"33","author":"Phan","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2024.11.064_bib17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/CCID.S396430","article-title":"Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB-UVB phototherapy","volume":"16","author":"Li","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib19","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/jocd.15537","article-title":"The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non-segmental vitiligo","volume":"22","author":"Yousefian","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib20","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jaad.2024.11.064_bib21","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2024.11.064_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaci.2023.09.021","article-title":"Improvements in immune\/melanocyte biomarkers with JAK3\/TEC family kinase inhibitor ritlecitinib in vitiligo","volume":"153","author":"Guttman-Yassky","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2024.11.064_bib24","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaad.2016.12.041","article-title":"The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo","volume":"76","author":"Mohammad","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib25","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"},{"key":"10.1016\/j.jaad.2024.11.064_bib26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2230.2007.02514.x","article-title":"Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial","volume":"32","author":"Dell'Anna","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib27","doi-asserted-by":"crossref","first-page":"e1423","DOI":"10.1111\/jdv.19347","article-title":"Combination of NB-UVB phototherapy and oral vitamin D supplementation in patients with generalized vitiligo: a randomized, triple-blind, placebo-controlled clinical trial","volume":"37","author":"Garza-Davila","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2024.11.064_bib28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/phpp.12918","article-title":"Efficacy of using oral methotrexate with phototherapy in the treatment of vitiligo in comparison with single phototherapy treatment: a double-blinded randomized controlled trial","volume":"39","author":"Lajevardi","year":"2023","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2024.11.064_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.det.2019.08.005","article-title":"Phototherapy for vitiligo","volume":"38","author":"Zubair","year":"2020","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2024.11.064_bib30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40264-015-0285-9","article-title":"Chimeric fusion proteins used for therapy: indications, mechanisms, and safety","volume":"38","author":"Baldo","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2024.11.064_bib31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0781.2006.00222.x","article-title":"Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites","volume":"22","author":"Anbar","year":"2006","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2024.11.064_bib32","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1468-3083.2006.02035.x","article-title":"Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study","volume":"21","author":"Bhatnagar","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2024.11.064_bib33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2006.09.004","article-title":"Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy","volume":"56","author":"Nicolaidou","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/phpp.12072","article-title":"Psoralen-narrowband UVB phototherapy for the treatment of vitiligo in comparison to narrowband UVB alone","volume":"29","author":"Bansal","year":"2013","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2024.11.064_bib35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2024.11.064_bib36","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1365-2133.2004.06321.x","article-title":"Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients","volume":"152","author":"Hofer","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2024.11.064_bib37","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2340\/00015555-2889","article-title":"Predictive model for response rate to narrowband ultraviolet B phototherapy in vitiligo: a retrospective cohort study of 579 patients","volume":"98","author":"Cabrera","year":"2018","journal-title":"Acta Derm Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224033814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224033814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:11:58Z","timestamp":1742357518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224033814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0190962224033814"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.11.064","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.11.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}